Literature DB >> 9579214

Primaquine-tolerant vivax malaria in Thailand.

S Looareesuwan1, K Buchachart, P Wilairatana, K Chalermrut, Y Rattanapong, S Amradee, S Siripiphat, S Chullawichit, K Thimasan, M Ittiverakul, A Triampon, D S Walsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9579214     DOI： 10.1080/00034989760338

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN： 0003-4983


× No keyword cloud information.
  14 in total

1.  Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia.

Authors:  Patricia Mula; Amalia Fernández-Martínez; Aida de Lucio; Jose Manuel Ramos; Francisco Reyes; Vicenta González; Agustín Benito; Pedro Berzosa
Journal:  Malar J       Date:  2011-08-02       Impact factor: 2.979

Review 2.  Combating malaria with nanotechnology-based targeted and combinatorial drug delivery strategies.

Authors:  Miloni Thakkar; Brijesh S
Journal:  Drug Deliv Transl Res       Date:  2016-08       Impact factor: 4.617

3.  Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.

Authors:  Srivicha Krudsood; Polrat Wilairatana; Noppadon Tangpukdee; Kobsiri Chalermrut; Siripun Srivilairit; Vipa Thanachartwet; Sant Muangnoicharoen; Natthanej Luplertlop; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Korean J Parasitol       Date:  2006-09       Impact factor: 1.341

4.  Recent Advances in the Prophylaxis and Treatment of Malaria.

Authors:  Annie-Claude Labbé; Mona R. Loutfy; Kevin C. Kain
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

5.  High-dose primaquine regimens against relapse of Plasmodium vivax malaria.

Authors:  Srivicha Krudsood; Noppadon Tangpukdee; Polrat Wilairatana; Nantaporn Phophak; J Kevin Baird; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Am J Trop Med Hyg       Date:  2008-05       Impact factor: 2.345

6.  Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand.

Authors:  Udomsak Silachamroon; Srivicha Krudsood; Sombat Treeprasertsuk; Polrat Wilairatana; Kobsiri Chalearmrult; Hla Yin Mint; Pannamas Maneekan; Nicholas J White; Victor R Gourdeuk; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Am J Trop Med Hyg       Date:  2003-07       Impact factor: 2.345

Review 7.  Primaquine treatment and relapse in Plasmodium vivax malaria.

Authors:  Kumar Rishikesh; Kavitha Saravu
Journal:  Pathog Glob Health       Date:  2016-02-18       Impact factor: 2.894

8.  Differential prevalence of Plasmodium infections and cryptic Plasmodium knowlesi malaria in humans in Thailand.

Authors:  Chaturong Putaporntip; Thongchai Hongsrimuang; Sunee Seethamchai; Teerayot Kobasa; Kriengsak Limkittikul; Liwang Cui; Somchai Jongwutiwes
Journal:  J Infect Dis       Date:  2009-04-15       Impact factor: 5.226

9.  Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse.

Authors:  Louis Macareo; Khin Maung Lwin; Phaik Yeong Cheah; Prayoon Yuentrakul; R Scott Miller; Francois Nosten
Journal:  Malar J       Date:  2013-05-29       Impact factor: 2.979

10.  A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan.

Authors:  Toby Leslie; Ismail Mayan; Nasir Mohammed; Panna Erasmus; Jan Kolaczinski; Christopher J M Whitty; Mark Rowland
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.